항암플러스를 투여한 4기 전이성 위암환자에 대한 전향적 생존률 분석. Chin J Integr Med. 20(1):49-55, 2014
Survival Analysis of Stage Ⅳ Metastatic Gastric Cancer Patients Treated with HangAm-Plus. Chin J Integr Med. 2014 Jan;20(1):49-55.
2008년 1월-2009년 9월까지 본원에 내원한 127명 위암환자 중 ECOG performance status<2 인 환자
- HAP was taken 3times a day
- Patients were divided into two arms depending on the types of treatment received, one group that received HAP only and combined therapy group that received conventional chemotherapy along with HAP. There were 18 patients in HAP group and 26 patients in combined group. Each group was then subdivided by patients' chemo-history and their lines of chemotherapy.
- The results have shown the combined treatment to be more beneficial than the sole HAP treatment.
- This study supports the safety and potential efficacy of HAP treatment for prevention of chemo-related side effects when used along with conventional palliative chemotherapy.